Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

New Upgrade:   Dedicated Screeners for Stocks & ETFs

Learn more
Market News Market Pulse Stocks News ETF News Crypto News

Rapport Therapeutics, Inc.

Contributing Author

Recent Articles by Rapport Therapeutics, Inc.

Oct-28
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement RAPP -18.30% GlobeNewswire
Oct-27
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement RAPP +8.72% GlobeNewswire
Oct-20
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania RAPP GlobeNewswire
Sep-02
Rapport Therapeutics to Participate in Upcoming Investor Conferences RAPP GlobeNewswire
Aug-24
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program RAPP GlobeNewswire
Aug-05
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAPP GlobeNewswire
May-20
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference RAPP GlobeNewswire
May-07
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update RAPP +7.74% GlobeNewswire
Apr-21
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting RAPP GlobeNewswire
Apr-01
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting RAPP GlobeNewswire
Mar-10
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update RAPP GlobeNewswire
Mar-09
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China RAPP GlobeNewswire
Feb-24
Rapport Therapeutics to Participate in Upcoming Investor Conferences RAPP GlobeNewswire
Jan-07
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline RAPP +8.89% GlobeNewswire
Dec-18
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference RAPP GlobeNewswire
Dec-05
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures RAPP GlobeNewswire
Nov-25
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting RAPP GlobeNewswire
Nov-06
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update RAPP GlobeNewswire
Nov-05
Rapport Therapeutics to Participate in Upcoming Investor Conferences RAPP GlobeNewswire
Sep-11
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit RAPP GlobeNewswire
Sep-09
Rapport Announces Pricing of Public Offering of Common Stock RAPP -20.09% GlobeNewswire
Sep-08
Rapport Announces Proposed Public Offering of Common Stock RAPP +119.15% GlobeNewswire
Sep-08
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures RAPP +119.15% GlobeNewswire
Sep-05
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 RAPP -6.45% GlobeNewswire
Aug-07
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update RAPP +5.48% GlobeNewswire
Jun-02
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates RAPP +13.66% RAPP +30.21% GlobeNewswire
May-27
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference RAPP -7.21% GlobeNewswire
May-21
Rapport Therapeutics to Host 2025 Investor and Analyst Day RAPP GlobeNewswire
May-08
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update RAPP GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)